A randomized, phase 2 study of deoxyuridine triphosphatase inhibitor, TAS-114, in combination with S-1 versus S-1 alone in patients with advanced non-small-cell lung cancer.
Aged
Antineoplastic Agents
/ administration & dosage
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Drug Combinations
Female
Humans
Lung Neoplasms
/ drug therapy
Male
Middle Aged
Oxonic Acid
/ administration & dosage
Pyrimidines
/ administration & dosage
Pyrophosphatases
/ antagonists & inhibitors
Sulfonamides
/ administration & dosage
Tegafur
/ administration & dosage
Treatment Outcome
5-fluorouracil
Non-small-cell lung cancer
Progression-free survival
dUTPase
Journal
Investigational new drugs
ISSN: 1573-0646
Titre abrégé: Invest New Drugs
Pays: United States
ID NLM: 8309330
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
26
02
2020
accepted:
20
03
2020
pubmed:
5
4
2020
medline:
3
9
2021
entrez:
5
4
2020
Statut:
ppublish
Résumé
Introduction TAS-114 is a potent inhibitor of deoxyuridine triphosphatase, which is a gatekeeper protein preventing uracil and 5-fluorouracil (5-FU) misincorporation into DNA. TAS-114 has been suggested to enhance the antitumor activity of 5-FU. This randomized, phase 2 study investigated TAS-114 plus S-1 (TAS-114/S-1) vs. S-1 in non-small-cell lung cancer (NSCLC) patients. Methods Patients with advanced NSCLC, previously treated with ≥ 2 regimens, were randomized 1:1 to receive TAS-114 (400 mg)/S-1 (30 mg/m
Identifiants
pubmed: 32246224
doi: 10.1007/s10637-020-00930-5
pii: 10.1007/s10637-020-00930-5
pmc: PMC7497678
doi:
Substances chimiques
Antineoplastic Agents
0
Drug Combinations
0
Pyrimidines
0
Sulfonamides
0
TAS-114
0
S 1 (combination)
150863-82-4
Tegafur
1548R74NSZ
Oxonic Acid
5VT6420TIG
Pyrophosphatases
EC 3.6.1.-
dUTP pyrophosphatase
EC 3.6.1.23
Banques de données
ClinicalTrials.gov
['NCT02855125']
Types de publication
Clinical Trial, Phase II
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1588-1597Références
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424. https://doi.org/10.3322/caac.21492
doi: 10.3322/caac.21492
Barnet MB, Cooper WA, Boyer MJ, Kao S (2018) Immunotherapy in non-small cell lung cancer: shifting prognostic paradigms. J Clin Med 7(6):151. https://doi.org/10.3390/jcm7060151
National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Non-small cell lung cancer. Version 2.2018. https://www2.tri-kobe.org/nccn/guideline/lung/english/non_small.pdf . Accessed 1 Aug 2019
Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, Mok TS, Reck M, Van Schil PE, Hellmann MD, Peters S (2019) Correction to: “Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”. Ann Oncol 30(5):863–870. https://doi.org/10.1093/annonc/mdy474
Takeda K (2013) Clinical development of S-1 for non-small cell lung cancer: a Japanese perspective. Ther Adv Med Oncol 5(5):301–311. https://doi.org/10.1177/1758834013500702
doi: 10.1177/1758834013500702
pubmed: 23997830
pmcid: 3752178
Nokihara H, Lu S, Mok TSK, Nakagawa K, Yamamoto N, Shi YK, Zhang L, Soo RA, Yang JC, Sugawara S, Nishio M, Takahashi T, Goto K, Chang J, Maemondo M, Ichinose Y, Cheng Y, Lim WT, Morita S, Tamura T (2017) Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer). Ann Oncol 28(11):2698–2706. https://doi.org/10.1093/annonc/mdx419
doi: 10.1093/annonc/mdx419
pubmed: 29045553
pmcid: 5834128
Saito K, Nagashima H, Noguchi K, Yoshisue K, Yokogawa T, Matsushima E, Tahara T, Takagi S (2014) First-in-human, phase I dose-escalation study of single and multiple doses of a first-in-class enhancer of fluoropyrimidines, a dUTPase inhibitor (TAS-114) in healthy male volunteers. Cancer Chemother Pharmacol 73(3):577–583. https://doi.org/10.1007/s00280-014-2383-2
doi: 10.1007/s00280-014-2383-2
pubmed: 24452393
Yano W, Yokogawa T, Wakasa T, Yamamura K, Fujioka A, Yoshisue K, Matsushima E, Miyahara S, Miyakoshi H, Taguchi J, Chong KT, Takao Y, Fukuoka M, Matsuo K (2018) TAS-114, a first-in-class dual dUTPase/DPD inhibitor, demonstrates potential to improve therapeutic efficacy of fluoropyrimidine-based chemotherapy. Mol Cancer Ther 17(8):1683–1693. https://doi.org/10.1158/1535-7163.Mct-17-0911
Doi T, Yoh K, Shitara K, Takahashi H, Ueno M, Kobayashi S, Morimoto M, Okusaka T, Ueno H, Morizane C, Okano N, Nagashima F, Furuse J (2019) First-in-human phase 1 study of novel dUTPase inhibitor TAS-114 in combination with S-1 in Japanese patients with advanced solid tumors. Invest New Drugs 37(3):507–518. https://doi.org/10.1007/s10637-018-0697-3
doi: 10.1007/s10637-018-0697-3
pubmed: 30511200
Fasolo A, Aoyama T, Stathis A et al. A large phase I study of TAS-114 in combination with S-1 in patients with advanced solid tumors. Proceedings: AACR Annual Meeting 2018; 14–18 April 2018; Chicago, IL. Abstract #CT014. https://cancerres.aacrjournals.org/content/78/13_Supplement/CT014
Govindan R, Morgensztern D, Kommor MD, Herbst RS, Schaefer P, Gandhi J, Saito K, Zergebel C, Schiller J (2011) Phase II trial of S-1 as second-line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol 6(4):790–795. https://doi.org/10.1097/JTO.0b013e3182103b51
doi: 10.1097/JTO.0b013e3182103b51
pubmed: 21325974
Ono A, Naito T, Murakami H, Takahashi T, Nakamura Y, Tsuya A, Kaira K, Igawa S, Shukuya T, Tamiya A, Kaira R, Endo M, Yamamoto N (2010) Evaluation of S-1 as third- or further-line chemotherapy in advanced non-small-cell lung cancer. Int J Clin Oncol 15(2):161–165. https://doi.org/10.1007/s10147-010-0034-0
doi: 10.1007/s10147-010-0034-0
pubmed: 20198400
Miyoshi S, Ito R, Katayama H, Kadowaki T, Yano S, Watanabe A, Abe M, Hamada H, Okura T, Higaki J (2014) Phase II trial of S-1 as third-line or further chemotherapy in patients with advanced non-small-cell lung cancer. Int J Clin Oncol 19(6):1005–1010. https://doi.org/10.1007/s10147-014-0663-9
doi: 10.1007/s10147-014-0663-9
pubmed: 24532162
Dodd LE, Korn EL, Freidlin B, Jaffe CC, Rubinstein LV, Dancey J, Mooney MM (2008) Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense? J Clin Oncol 26(22):3791–3796. https://doi.org/10.1200/jco.2008.16.1711
doi: 10.1200/jco.2008.16.1711
pubmed: 18669467
pmcid: 2654812
Simmons CP, Koinis F, Fallon MT, Fearon KC, Bowden J, Solheim TS, Gronberg BH, McMillan DC, Gioulbasanis I, Laird BJ (2015) Prognosis in advanced lung cancer–A prospective study examining key clinicopathological factors. Lung Cancer 88(3):304–309. https://doi.org/10.1016/j.lungcan.2015.03.020
doi: 10.1016/j.lungcan.2015.03.020
pubmed: 25870155
Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S, Hatooka S, Shinoda M, Takahashi T, Yatabe Y (2005) Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 23(11):2513–2520. https://doi.org/10.1200/jco.2005.00.992
doi: 10.1200/jco.2005.00.992
pubmed: 15738541
Gandara DR, Grimminger P, Mack PC, Lara PN Jr, Li T, Danenberg PV, Danenberg KD (2010) Association of epidermal growth factor receptor activating mutations with low ERCC1 gene expression in non-small cell lung cancer. J Thorac Oncol 5(12):1933–1938. https://doi.org/10.1097/JTO.0b013e3181fd418d
doi: 10.1097/JTO.0b013e3181fd418d
pubmed: 20975603
Pfaffle HN, Wang M, Gheorghiu L, Ferraiolo N, Greninger P, Borgmann K, Settleman J, Benes CH, Sequist LV, Zou L, Willers H (2013) EGFR-activating mutations correlate with a Fanconi anemia-like cellular phenotype that includes PARP inhibitor sensitivity. Cancer Res 73(20):6254–6263. https://doi.org/10.1158/0008-5472.Can-13-0044
doi: 10.1158/0008-5472.Can-13-0044
pubmed: 23966292
Tsukioka S, Yano W, Yokogawa T et al. Expression of DNA damage repair enzymes determine the efficacy of a novel dUTPase inhibitor, TAS-114. Presented at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, Boston, MA, USA, 19–23 October 2013. https://mct.aacrjournals.org/content/12/11_Supplement/B89
Zhou JX, Feng LJ, Zhang X (2017) Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials. Drug Des Devel Ther 11:3009–3017. https://doi.org/10.2147/dddt.S147726
doi: 10.2147/dddt.S147726
pubmed: 29075104
pmcid: 5648323
Suenaga M, Schirripa M, Cao S, Zhang W, Yang D, Murgioni S, Rossini D, Marmorino F, Mennitto A, Ning Y, Okazaki S, Berger MD, Miyamoto Y, Gopez R Jr, Barzi A, Yamaguchi T, Loupakis F, Lenz HJ (2017) Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer. Ann Oncol 28(5):1015–1022. https://doi.org/10.1093/annonc/mdx035
doi: 10.1093/annonc/mdx035
pubmed: 28453695
pmcid: 5834058